author-photo

D. Vassilief

13

Papers

370

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM

2010 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (175)
Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

2009 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (15)
Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

2006 Blood
Show All
- Source
- Cite
- Save
Citations (1)
RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.

2006 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

2006 Blood
Show All
- Source
- Cite
- Save
Citations (5)
Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

2005 Blood
Show All
- Source
- Cite
- Save
Citations (3)
A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes : the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies

2005 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (44)
Evaluation of the impact of information about treatment-related risks in patients receiving blood-derived or recombinant medications.

2004 Haemophilia
Show All
- Source
- Cite
- Save
Citations (6)
High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study.

2004 Blood
Show All
- Source
- Cite
- Save
Citations (15)
Thalidomide for the Treatment of Low Risk Myelodysplasia.

2004 Blood
Show All
- Source
- Cite
- Save
Citations (3)